Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United S…
$132.37+1.98%
报价 2026-11-06
市值
$6.96B
EV
$11.76B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -48.1%
$129.80$255.17
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AXSMAxsome Therapeutics, Inc. | $6.96B | +2.0% | +54.8% | 92.6% | – | – | – | |
| JAZZJazz Pharmaceuticals plc | $15.07B | +3.3% | – | 88.2% | – | 109.6x | – | |
| PCVXVaxcyte, Inc. | $10.06B | +3.2% | +4900.0% | 0% | – | – | – | |
| ARWRArrowhead Pharmaceuticals, Inc. | $8.22B | +1.2% | -28.9% | 100% | – | – | – | |
| RYTMRhythm Pharmaceuticals, Inc. | $7.73B | +6.9% | +57.7% | 88.2% | – | – | – | |
| ABVXAbivax S.A. | $7.5B | +1.8% | – | 0% | – | – | – | |
| CYTKCytokinetics, Incorporated | $7.46B | -3.3% | +35.4% | -22.3% | – | – | – | |
| CRSPCRISPR Therapeutics AG | $4.86B | +3.1% | – | -1,534.4% | – | – | – | |
| 同行中位数 | – | – | +46.5% | 0% | – | 109.6x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。